Completed PHASE2 INTERVENTIONAL 1-arm NCT01907490

Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation

A Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically Under Maximal Use Conditions for the Treatment of Head Lice Infestation.

Sponsor: Accelovance

Conditions Head Lice Infestation

Interventions Ha44 Gel

Updated 9 times since 2017 Last updated: Apr 20, 2020 Started: Mar 31, 2013 Primary completion: Jul 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Head Lice Infestation and is currently completed. Accelovance leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

May 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — May 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Accelovance
Dr. Reddy's Laboratories Limited
Target Health Inc.

Data source: Dr. Reddy's Laboratories Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.